US 12,281,324 B2
Exogenous gene expression in recombinant adenovirus for minimal impact on viral kinetics
Clodagh O'Shea, San Diego, CA (US); William Partlo, San Diego, CA (US); and Colin Powers, San Diego, CA (US)
Assigned to Salk Institute for Biological Studies, La Jolla, CA (US)
Filed by Salk Institute for Biological Studies, La Jolla, CA (US)
Filed on Jun. 29, 2022, as Appl. No. 17/852,891.
Application 17/852,891 is a continuation of application No. 16/916,764, filed on Jun. 30, 2020, granted, now 11,401,529.
Application 16/916,764 is a continuation of application No. 16/110,207, filed on Aug. 23, 2018, granted, now 10,738,325, issued on Aug. 11, 2020.
Application 16/110,207 is a continuation of application No. PCT/US2017/019086, filed on Feb. 23, 2017.
Claims priority of provisional application 62/298,653, filed on Feb. 23, 2016.
Prior Publication US 2023/0088476 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/86 (2006.01)
CPC C12N 15/86 (2013.01) [C12N 2710/10011 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/10051 (2013.01); C12N 2840/00 (2013.01)] 35 Claims
 
1. A recombinant adenovirus genome, comprising a heterologous open reading frame (ORF) and a self-cleaving peptide coding sequence, both operably linked to and in the same reading frame as an endogenous adenovirus ORF, wherein the self-cleaving peptide coding sequence is located between the heterologous ORF and the endogenous ORF, and wherein:
the endogenous ORF is E1B-55k and the heterologous ORF is 3′ of E1B-55k;
the endogenous ORF is DNA polymerase and the heterologous ORF is 5′ of DNA polymerase;
the endogenous ORF is DNA-binding protein (DBP) and the heterologous ORF is 3′ of DBP;
the endogenous ORF is adenovirus death protein (ADP) and the heterologous ORF is 5′ of ADP;
the endogenous ORF is E3-14.7k and the heterologous ORF is 3′ of E3-14.7k;
the endogenous ORF is E4-ORF2 and the heterologous ORF is 5′ of E4-ORF2; or
the endogenous ORF is fiber and the heterologous ORF is 3′ of fiber.